BR112014000908A2 - composto, composição farmacêutica e respectivos usos e métodos para tratar hipogonadismo secundário ou distúrbio associado ao mesmo, infertilidade em mulher, diabetes do tipo 2 em humano do sexo masculino, câncer da mama em mulher e câncer do endomètrio, do ovàrio ou uterino em mulher, para prevenir a transição da síndrome metabólica para diabetes do tipo 2 em humano do sexo masculino e câncer da mama em mulher e para reduzir níveis de glicose no sangue em jejum de humano do sexo masculino - Google Patents
composto, composição farmacêutica e respectivos usos e métodos para tratar hipogonadismo secundário ou distúrbio associado ao mesmo, infertilidade em mulher, diabetes do tipo 2 em humano do sexo masculino, câncer da mama em mulher e câncer do endomètrio, do ovàrio ou uterino em mulher, para prevenir a transição da síndrome metabólica para diabetes do tipo 2 em humano do sexo masculino e câncer da mama em mulher e para reduzir níveis de glicose no sangue em jejum de humano do sexo masculinoInfo
- Publication number
- BR112014000908A2 BR112014000908A2 BR112014000908A BR112014000908A BR112014000908A2 BR 112014000908 A2 BR112014000908 A2 BR 112014000908A2 BR 112014000908 A BR112014000908 A BR 112014000908A BR 112014000908 A BR112014000908 A BR 112014000908A BR 112014000908 A2 BR112014000908 A2 BR 112014000908A2
- Authority
- BR
- Brazil
- Prior art keywords
- women
- diabetes
- type
- breast cancer
- male
- Prior art date
Links
- 206010006187 Breast cancer Diseases 0.000 title 2
- 208000026310 Breast neoplasm Diseases 0.000 title 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 title 2
- 206010014733 Endometrial cancer Diseases 0.000 title 1
- 206010014759 Endometrial neoplasm Diseases 0.000 title 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 title 1
- 241000282412 Homo Species 0.000 title 1
- 208000001145 Metabolic Syndrome Diseases 0.000 title 1
- 206010033128 Ovarian cancer Diseases 0.000 title 1
- 206010061535 Ovarian neoplasm Diseases 0.000 title 1
- 206010059594 Secondary hypogonadism Diseases 0.000 title 1
- 208000002495 Uterine Neoplasms Diseases 0.000 title 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 title 1
- 239000008280 blood Substances 0.000 title 1
- 210000004369 blood Anatomy 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 208000035475 disorder Diseases 0.000 title 1
- 230000002357 endometrial effect Effects 0.000 title 1
- 239000008103 glucose Substances 0.000 title 1
- 201000003368 hypogonadotropic hypogonadism Diseases 0.000 title 1
- 208000000509 infertility Diseases 0.000 title 1
- 230000036512 infertility Effects 0.000 title 1
- 231100000535 infertility Toxicity 0.000 title 1
- 230000002611 ovarian Effects 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 230000007704 transition Effects 0.000 title 1
- 206010046766 uterine cancer Diseases 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C217/06—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
- C07C217/14—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring
- C07C217/18—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Gynecology & Obstetrics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pregnancy & Childbirth (AREA)
- Neurology (AREA)
- Emergency Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161515278P | 2011-08-04 | 2011-08-04 | |
| PCT/US2012/049451 WO2013020017A1 (en) | 2011-08-04 | 2012-08-03 | Trans-clomiphene metabolites and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112014000908A2 true BR112014000908A2 (pt) | 2017-02-21 |
Family
ID=46724628
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112014000908A BR112014000908A2 (pt) | 2011-08-04 | 2012-08-03 | composto, composição farmacêutica e respectivos usos e métodos para tratar hipogonadismo secundário ou distúrbio associado ao mesmo, infertilidade em mulher, diabetes do tipo 2 em humano do sexo masculino, câncer da mama em mulher e câncer do endomètrio, do ovàrio ou uterino em mulher, para prevenir a transição da síndrome metabólica para diabetes do tipo 2 em humano do sexo masculino e câncer da mama em mulher e para reduzir níveis de glicose no sangue em jejum de humano do sexo masculino |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US9981906B2 (https=) |
| EP (2) | EP3351527A1 (https=) |
| JP (2) | JP6433785B2 (https=) |
| KR (1) | KR20140054110A (https=) |
| CN (1) | CN103702975B (https=) |
| AU (2) | AU2012289964B2 (https=) |
| BR (1) | BR112014000908A2 (https=) |
| CA (1) | CA2841572C (https=) |
| CL (1) | CL2014000268A1 (https=) |
| CO (1) | CO6862154A2 (https=) |
| CR (1) | CR20140124A (https=) |
| EA (1) | EA201490416A1 (https=) |
| IL (1) | IL230287B (https=) |
| MX (1) | MX355316B (https=) |
| MY (2) | MY191802A (https=) |
| NI (1) | NI201400008A (https=) |
| PH (1) | PH12014500144A1 (https=) |
| SG (1) | SG10201606425WA (https=) |
| UA (1) | UA113291C2 (https=) |
| WO (1) | WO2013020017A1 (https=) |
| ZA (1) | ZA201400406B (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120284764A1 (en) * | 2011-05-05 | 2012-11-08 | Keith Ball | Method and system for requesting services by a media device |
| UA113291C2 (xx) | 2011-08-04 | 2017-01-10 | Метаболіти транскломіфену і їх застосування | |
| SG11201407397WA (en) | 2012-05-31 | 2014-12-30 | Repros Therapeutics Inc | Formulations and methods for vaginal delivery of antiprogestins |
| ES2688821T3 (es) | 2012-11-02 | 2018-11-07 | Repros Therapeutics Inc. | Métodos y composiciones para tratar afecciones dependientes de la progesterona |
| WO2014070523A1 (en) * | 2012-11-02 | 2014-05-08 | Repros Therapeutics Inc. | Trans-clomiphene for use in cancer therapy |
| WO2017123577A1 (en) * | 2016-01-12 | 2017-07-20 | Repros Therapeutics Inc. | Trans-clomiphene and progesterone receptor antagonist combination therapy for treating hormone-dependent conditions |
| CN108883083A (zh) * | 2016-02-25 | 2018-11-23 | 艾森潘帕克制药股份有限公司 | 两种氯米芬异构体的口服剂型及使用其治疗继发性腺功能减退症的方法 |
| WO2017182097A1 (en) | 2016-04-22 | 2017-10-26 | F.I.S. - Fabbrica Italiana Sintetici S.P.A. | Process for the preparation of enclomiphene citrate having needle shaped crystal habit. |
Family Cites Families (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2914563A (en) | 1957-08-06 | 1959-11-24 | Wm S Merrell Co | Therapeutic composition |
| IT951631B (it) | 1971-03-18 | 1973-07-10 | Richardson Merrell Spa | Composti utili per la separazione di isomeri ottici geometrici e strutturali e relativo procedimen to di sintesi |
| US4061733A (en) | 1976-10-15 | 1977-12-06 | Narayan Vishwanath Gunjikar | Veterinary compositions for inducing estrus in animals and method |
| US4729999A (en) | 1984-10-12 | 1988-03-08 | Bcm Technologies | Antiestrogen therapy for symptoms of estrogen deficiency |
| DE3660489D1 (en) | 1985-06-08 | 1988-09-15 | Asta Pharma Ag | Derivatives of 1,1,2,2-tetramethyl-1,2-bis(2-fluoro-4-hydroxyphenyl) ethane |
| US4820736A (en) * | 1987-03-20 | 1989-04-11 | Yale University | Use of clomiphene to predict fertility in a human female |
| GB8926171D0 (en) | 1989-11-20 | 1990-01-10 | Applied Research Systems | Treatment of infertility |
| JPH04312522A (ja) | 1991-04-08 | 1992-11-04 | Yoshiaki Kawashima | 徐放性錠剤の製造方法 |
| US5681585A (en) | 1991-12-24 | 1997-10-28 | Euro-Celtique, S.A. | Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| KR100326962B1 (ko) | 1992-09-15 | 2002-12-02 | 메렐 파마슈티칼스 인크. | 타목시펜-내성종양치료용비대사성클로미펜유사체 |
| US5776923A (en) | 1993-01-19 | 1998-07-07 | Endorecherche, Inc. | Method of treating or preventing osteoporosis by adminstering dehydropiandrosterone |
| GB9405304D0 (en) | 1994-03-16 | 1994-04-27 | Scherer Ltd R P | Delivery systems for hydrophobic drugs |
| AU2638795A (en) | 1994-06-17 | 1996-01-15 | University Of Nebraska Board Of Regents | In situ gel-forming delivery vehicle for bio-affecting substances, and method of use |
| DE4435368A1 (de) | 1994-09-22 | 1996-03-28 | Schering Ag | Verwendung von Aromatasehemmern zur Herstellung eines Arzneimittels zur Behandlung eines relativen Androgenmangels beim Mann |
| AU6824996A (en) | 1995-08-17 | 1997-03-12 | Dyer, Alison Margaret | Controlled release products |
| US5773031A (en) | 1996-02-27 | 1998-06-30 | L. Perrigo Company | Acetaminophen sustained-release formulation |
| IL120262A (en) | 1996-02-28 | 2001-01-28 | Pfizer | Droloxifene and derivatives thereof for use in increasing serum testosterone levels |
| JP2002511777A (ja) | 1996-10-28 | 2002-04-16 | ゼネラル ミルズ，インコーポレイテッド | 調放性粒子の埋包およびカプセル化 |
| ATE279461T1 (de) | 1997-04-03 | 2004-10-15 | Guilford Pharm Inc | Bioabbaubare terephthalat polyester-polyphosphat polymere, zusammensetzungen, gegenstände und verfahren für ihre herstellung und verwendung |
| US6653297B1 (en) | 1997-07-03 | 2003-11-25 | Medical College Of Hampton Roads | Control of selective estrogen receptor modulators |
| US6342250B1 (en) | 1997-09-25 | 2002-01-29 | Gel-Del Technologies, Inc. | Drug delivery devices comprising biodegradable protein for the controlled release of pharmacologically active agents and method of making the drug delivery devices |
| US6413533B1 (en) | 1998-05-07 | 2002-07-02 | The University Of Tennessee Research Corporation | Method for chemoprevention of prostate cancer |
| US20040186185A1 (en) | 1998-05-07 | 2004-09-23 | Steiner Mitchell S. | Method for treatment and chemoprevention of prostate cancer |
| MXPA01000794A (es) | 1998-07-30 | 2002-04-08 | Stoller Ets | Tratamiento de plantas con acido salicilico y aminas organicas. |
| WO2000007996A2 (en) | 1998-08-07 | 2000-02-17 | Chiron Corporation | Pyrazoles as estrogen receptor modulators |
| US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| TR200200406T2 (tr) | 1999-06-11 | 2002-06-21 | Watson Pharmaceuticals, Inc. | Kadınlara oral olmayan yollarla androjenik steroidlerin uygulanması |
| CA2321321A1 (en) | 1999-09-30 | 2001-03-30 | Isotis B.V. | Polymers loaded with bioactive agents |
| US6258802B1 (en) | 1999-10-06 | 2001-07-10 | Medical College Of Hampton Roads | Corticoid therapy |
| WO2001052823A2 (en) | 2000-01-20 | 2001-07-26 | Noven Pharmaceuticals, Inc. | Compositions to effect the release profile in the transdermal administration of drugs |
| CN1400904A (zh) | 2000-01-28 | 2003-03-05 | 恩多研究公司 | 与雌激素联合的选择性雌激素受体调节剂 |
| US7067557B2 (en) | 2000-05-26 | 2006-06-27 | Harry Fisch | Methods of treating androgen deficiency in men using selective antiestrogens |
| JP2003534375A (ja) | 2000-05-26 | 2003-11-18 | フィッチ，ハリー | 選択性抗エストロゲン薬を用いた男性におけるアンドロゲン欠乏症の治療法 |
| JP2004507465A (ja) | 2000-08-11 | 2004-03-11 | ワイス | エストロゲン受容体陽性癌腫の治療方法 |
| US6503894B1 (en) | 2000-08-30 | 2003-01-07 | Unimed Pharmaceuticals, Inc. | Pharmaceutical composition and method for treating hypogonadism |
| WO2002030355A2 (en) | 2000-10-11 | 2002-04-18 | Laura Kragie | Composition and method of alleviating adverse side effects and/or enhancing efficacy of agents that inhibit aromatase |
| US6743448B2 (en) | 2000-12-11 | 2004-06-01 | Abraham H. Kryger | Topical testosterone formulations and associated methods |
| PL211339B1 (pl) | 2001-07-09 | 2012-05-31 | Zonagen | Zastosowanie kompozycji do wytwarzania leku do leczenia niedoboru testosteronu u samców ssaków |
| US7173064B2 (en) | 2001-07-09 | 2007-02-06 | Repros Therapeutics Inc. | Methods and compositions with trans-clomiphene for treating wasting and lipodystrophy |
| US6645974B2 (en) | 2001-07-31 | 2003-11-11 | Merck & Co., Inc. | Androgen receptor modulators and methods for use thereof |
| CA2459943A1 (en) | 2001-09-21 | 2003-04-03 | Merck & Co., Inc. | Androstanes as androgen receptor modulators |
| US20060269611A1 (en) | 2001-11-29 | 2006-11-30 | Steiner Mitchell S | Prevention and treatment of androgen-deprivation induced osteoporosis |
| US7105679B2 (en) | 2001-12-19 | 2006-09-12 | Kanojia Ramesh M | Heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators |
| US7135575B2 (en) | 2003-03-03 | 2006-11-14 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
| US20050042268A1 (en) | 2003-07-16 | 2005-02-24 | Chaim Aschkenasy | Pharmaceutical composition and method for transdermal drug delivery |
| WO2006019916A1 (en) | 2004-07-14 | 2006-02-23 | Repros Therapeutics Inc. | Trans-clomiphene for the treatment of benign prostate hypertrophy, prostate cancer, hypogonadism, elevated triglycerides and high cholesterol |
| US20060293294A1 (en) | 2004-09-03 | 2006-12-28 | Hormos Medical Corporation | Method for treatment or prevention of androgen deficiency |
| CN101115709B (zh) * | 2004-12-13 | 2011-04-13 | 小野药品工业株式会社 | 氨基羧酸衍生物及其医药用途 |
| CA2595363C (en) | 2005-02-04 | 2012-03-27 | Repros Therapeutics Inc. | Methods and materials with trans-clomiphene for the treatment of male infertility |
| AU2006213856B2 (en) | 2005-02-11 | 2011-03-17 | Regeneron Pharmaceuticals, Inc. | Therapeutic combination of a VEGF antagonist (VEGF trap) and an anti-hypertensive agent |
| EP1865938A4 (en) * | 2005-03-22 | 2008-09-24 | Repros Therapeutics Inc | DOSAGE SCHEMES FOR TRANS-CLOMIPHENE |
| EP1896134A2 (en) | 2005-06-13 | 2008-03-12 | Rigel Pharmaceuticals, Inc. | Methods and compositions for treating degenerative bone disorders |
| BRPI0615165A2 (pt) * | 2005-08-05 | 2016-09-13 | Repros Therapeutics Inc | método de tratamento de infertilidade |
| US7613937B2 (en) | 2005-10-31 | 2009-11-03 | Hewlett-Packard Development Company, L.P. | Method and apparatus for utilizing a microcontroller to provide an automatic order and timing power and reset sequencer |
| JP2009527504A (ja) | 2006-02-23 | 2009-07-30 | イオメディックス スリープ インターナショナル エスアールエル | 良質な睡眠の誘導および維持のための組成物および方法 |
| EP1829534A1 (en) | 2006-03-02 | 2007-09-05 | Laboratorios Del Dr. Esteve, S.A. | Use of compounds binding to the sigma receptor for the treatment of metabolic syndrome |
| US20080112888A1 (en) | 2006-06-30 | 2008-05-15 | Schering Corporation | Igfbp2 biomarker |
| CN101766000A (zh) | 2007-06-26 | 2010-06-30 | 传媒专利有限公司 | 管理组播组的方法和设备 |
| WO2009020521A2 (en) | 2007-08-03 | 2009-02-12 | The Brigham And Women's Hospital, Inc. | Identification and treatment of estrogen responsive prostate tumors |
| SG185311A1 (en) * | 2007-10-16 | 2012-11-29 | Repros Therapeutics Inc | Trans-clomiphene for metabolic syndrome |
| US20100111901A1 (en) | 2008-11-03 | 2010-05-06 | Auspex Pharmaceuticals, Inc. | Triazole inhibitors of aromatase |
| TWI458478B (zh) | 2008-11-07 | 2014-11-01 | Repros Therapeutics Inc | 用於代謝症候群與第２型糖尿病的反式氯米芬 |
| US20100144687A1 (en) | 2008-12-05 | 2010-06-10 | Glaser Rebecca L | Pharmaceutical compositions containing testosterone and an aromatase inhibitor |
| UA113291C2 (xx) | 2011-08-04 | 2017-01-10 | Метаболіти транскломіфену і їх застосування | |
| CA2881604C (en) | 2011-08-09 | 2021-09-14 | Kenneth W. Adams | Use of aromatase inhibitor or estrogen blocker for increasing spermatogenesis or testosterone levels in males |
| JP2015508825A (ja) | 2012-02-29 | 2015-03-23 | レプロス セラピューティクス インコーポレイティド | アンドロゲン欠乏症を治療するための併用療法 |
| BR112015002288A2 (pt) | 2012-08-21 | 2017-07-04 | Repros Therapeutics Inc | formulações de trans-clomifeno e usos das mesmas |
| CN103351304B (zh) | 2013-07-01 | 2015-12-09 | 暨明医药科技（苏州）有限公司 | 一种克罗米芬的合成方法 |
-
2012
- 2012-03-08 UA UAA201402168A patent/UA113291C2/uk unknown
- 2012-08-03 JP JP2014524097A patent/JP6433785B2/ja not_active Expired - Fee Related
- 2012-08-03 AU AU2012289964A patent/AU2012289964B2/en not_active Ceased
- 2012-08-03 MY MYPI2017001676A patent/MY191802A/en unknown
- 2012-08-03 KR KR1020147004588A patent/KR20140054110A/ko not_active Ceased
- 2012-08-03 WO PCT/US2012/049451 patent/WO2013020017A1/en not_active Ceased
- 2012-08-03 PH PH1/2014/500144A patent/PH12014500144A1/en unknown
- 2012-08-03 BR BR112014000908A patent/BR112014000908A2/pt active Search and Examination
- 2012-08-03 EA EA201490416A patent/EA201490416A1/ru unknown
- 2012-08-03 EP EP18161551.9A patent/EP3351527A1/en not_active Withdrawn
- 2012-08-03 SG SG10201606425WA patent/SG10201606425WA/en unknown
- 2012-08-03 CN CN201280038230.6A patent/CN103702975B/zh not_active Expired - Fee Related
- 2012-08-03 EP EP12750508.9A patent/EP2744777A1/en not_active Withdrawn
- 2012-08-03 MY MYPI2014000022A patent/MY170718A/en unknown
- 2012-08-03 US US14/236,868 patent/US9981906B2/en not_active Expired - Fee Related
- 2012-08-03 MX MX2014000825A patent/MX355316B/es active IP Right Grant
- 2012-08-03 CA CA2841572A patent/CA2841572C/en not_active Expired - Fee Related
-
2014
- 2014-01-02 IL IL230287A patent/IL230287B/en active IP Right Grant
- 2014-01-17 ZA ZA2014/00406A patent/ZA201400406B/en unknown
- 2014-01-24 CO CO14014339A patent/CO6862154A2/es unknown
- 2014-01-30 NI NI201400008A patent/NI201400008A/es unknown
- 2014-02-03 CL CL2014000268A patent/CL2014000268A1/es unknown
- 2014-03-13 CR CR20140124A patent/CR20140124A/es unknown
-
2017
- 2017-06-20 AU AU2017204171A patent/AU2017204171A1/en not_active Abandoned
-
2018
- 2018-10-01 JP JP2018186696A patent/JP2019023210A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20140163114A1 (en) | 2014-06-12 |
| EP2744777A1 (en) | 2014-06-25 |
| CN103702975A (zh) | 2014-04-02 |
| NI201400008A (es) | 2015-12-10 |
| US9981906B2 (en) | 2018-05-29 |
| EA201490416A1 (ru) | 2014-11-28 |
| AU2012289964A1 (en) | 2014-01-30 |
| UA113291C2 (xx) | 2017-01-10 |
| KR20140054110A (ko) | 2014-05-08 |
| PH12014500144A1 (en) | 2014-02-24 |
| CL2014000268A1 (es) | 2014-11-14 |
| HK1196349A1 (zh) | 2014-12-12 |
| JP2014529584A (ja) | 2014-11-13 |
| SG10201606425WA (en) | 2016-09-29 |
| JP2019023210A (ja) | 2019-02-14 |
| IL230287B (en) | 2019-07-31 |
| NZ621892A (en) | 2016-03-31 |
| EP3351527A1 (en) | 2018-07-25 |
| CO6862154A2 (es) | 2014-02-10 |
| CA2841572A1 (en) | 2013-02-07 |
| AU2012289964B2 (en) | 2017-03-23 |
| MX355316B (es) | 2018-04-16 |
| CN103702975B (zh) | 2016-03-16 |
| WO2013020017A1 (en) | 2013-02-07 |
| JP6433785B2 (ja) | 2018-12-05 |
| CA2841572C (en) | 2020-10-13 |
| MY191802A (en) | 2022-07-15 |
| ZA201400406B (en) | 2014-11-26 |
| MX2014000825A (es) | 2014-02-27 |
| AU2017204171A1 (en) | 2017-07-13 |
| IL230287A0 (en) | 2014-03-06 |
| CR20140124A (es) | 2014-05-13 |
| MY170718A (en) | 2019-08-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112014000908A2 (pt) | composto, composição farmacêutica e respectivos usos e métodos para tratar hipogonadismo secundário ou distúrbio associado ao mesmo, infertilidade em mulher, diabetes do tipo 2 em humano do sexo masculino, câncer da mama em mulher e câncer do endomètrio, do ovàrio ou uterino em mulher, para prevenir a transição da síndrome metabólica para diabetes do tipo 2 em humano do sexo masculino e câncer da mama em mulher e para reduzir níveis de glicose no sangue em jejum de humano do sexo masculino | |
| IL244668A0 (en) | Compositions and formulations for prevention and treatment of diabetes and obesity, and methods of production and use thereof in glucose and caloric control | |
| WO2013151665A3 (en) | Modified polynucleotides for the production of proteins associated with human disease | |
| PL2643004T3 (pl) | Kompozycja oligosacharydów do leczenia chorób skóry | |
| BR112014031421A2 (pt) | composições para tratamento de câncer e métodos para produção das mesmas | |
| BR112015003397A2 (pt) | composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente. | |
| ZA201501977B (en) | Orally administered medical composition | |
| BR112015001098A2 (pt) | composto, composição farmacêutica e método para o tratamento de uma condição de doença. | |
| PT2768493T (pt) | Fitocanabinoides para utilização no tratamento do cancro da mama | |
| BR112015027400A2 (pt) | Anticorpos capazes de se ligar especificamente ao her2 | |
| BR112015010501A2 (pt) | composto, composição farmacêutica, nanopartículas, método para tratar câncer em um paciente e composição liofilizada | |
| WO2013188847A8 (en) | Compositions and methods for transmucosal absorption | |
| IL245908A0 (en) | Consequences of pyranochromanil phenol and a pharmaceutical preparation for the treatment of metabolic syndrome or inflammatory disease | |
| WO2014106001A3 (en) | Dual specific binding proteins having a receptor sequence | |
| MX2015013939A (es) | Composicion farmaceutica, metodos para tratamiento y sus usos. | |
| EP3067059A4 (en) | Pharmaceutical composition for preventing or treating thyroid diseases, containing lonicera caerulea l. var. edulis fruit extract as active ingredient | |
| IL234701A0 (en) | Strontium-containing complexes administered transdermally for the treatment of pain, itching and inflammation | |
| BR112013031712A2 (pt) | composto, composição farmacêutica, métodos para preparar um composto e para o tratamento de um distúrbio ou uma doença. | |
| BR112014016637A8 (pt) | composto, método para inibir a ligação de uma proteína iap a uma proteína caspase, método para tratar uma doença ou estado associado à sobre-expressão de uma iap em um mamífero, método para induzir apoptose em uma célula, método para sensibilizar uma célula a um sinal apoptótico, método para o tratamento do câncer, composição farmacêutica | |
| EP3006465A4 (en) | Anti-vegf antibody, and pharmaceutical composition for preventing, diagnosing or treating cancer or angiogenesis-related diseases, containing same | |
| EP2990040A4 (en) | Therapeutic agent for eyeground disease | |
| WO2015059463A3 (en) | Treatment of beta-catenin related diseases8 | |
| ZA201505196B (en) | Topical ophthalmological pharmaceutical composition containing regorafenib | |
| EP2959905A4 (en) | ORAL ADMINISTRATIVE ADSORBENT, THERAPEUTIC AGENT AGAINST CHILDING DISEASE AND THERAPEUTIC AGENT AGAINST LIVER DISEASES | |
| EP2959906A4 (en) | ADSORBENT FOR ORAL ADMINISTRATION, MEDICAMENT FOR RENAL DISEASE, AND MEDICAMENT FOR LIVER DISEASE |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2525 DE 28-05-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |